What Is Prediabetes — And Why Does It Matter?
Prediabetes is a metabolic condition in which blood sugar levels are higher than normal but not yet high enough to meet the diagnostic threshold for type 2 diabetes. It is not a minor finding — it is a strong, actionable warning that your metabolism is under serious stress, and that intervention now can prevent or significantly delay the development of type 2 diabetes.
The American Diabetes Association defines prediabetes using any one of three criteria:
- HbA1c (A1c): 5.7% to 6.4% (at or above 6.5% is diabetes)
- Fasting plasma glucose (FPG): 100 to 125 mg/dL (at or above 126 mg/dL is diabetes)
- 2-hour oral glucose tolerance test (OGTT): 140 to 199 mg/dL
If any one of these values falls in these ranges on two separate tests, the diagnosis is confirmed. Importantly, most people with prediabetes have no symptoms — which is exactly why routine screening is so important, especially in Georgia, where rates are elevated.
Prediabetes Prevalence in Georgia
Georgia consistently ranks among the states with higher-than-average rates of prediabetes and diabetes. According to CDC surveillance data, approximately 38% of American adults have prediabetes — yet the majority are unaware of it. In Georgia, estimates suggest roughly 3 million adults may have prediabetes, with particularly high rates among African American adults, Hispanic adults, and adults over 45. Savannah’s Chatham County and the broader Coastal Georgia region reflect these state-level trends.
The practical implication: if you are a patient in the Savannah, Pooler, or Hinesville area and you are overweight or have a family history of diabetes, there is a meaningful probability you have prediabetes — and you may not know it. A simple A1c test ordered at Scale Solutions during your initial evaluation can answer the question.
The Diabetes Prevention Program: What Lifestyle Alone Can Do
The landmark Diabetes Prevention Program (DPP), a major NIH-funded randomized trial, demonstrated that intensive lifestyle intervention — achieving a 7% reduction in body weight through diet and 150 minutes per week of moderate exercise — reduced the incidence of type 2 diabetes by approximately 58% over 3 years in high-risk adults with prediabetes. This remains the foundational evidence for lifestyle-based prevention.
That is an extraordinary result. But let’s be honest about the challenge: achieving and maintaining even a 7% weight reduction through lifestyle alone is something that most people, in real-world conditions outside a clinical trial, struggle to sustain. The DPP also showed that the drug metformin reduced diabetes risk by 31% — meaningful, but significantly less effective than lifestyle change at that weight-loss threshold.
This is precisely where GLP-1 medications enter the equation.
GLP-1 Evidence for Prediabetes Reversal
GLP-1 receptor agonists are not currently FDA-approved with a specific “prediabetes reversal” indication, but the clinical evidence for their benefit in this population is substantial and growing:
STEP-1 Trial Evidence (Semaglutide)
The STEP-1 trial, published in the New England Journal of Medicine in 2021, enrolled adults with obesity who did not have type 2 diabetes. Participants treated with semaglutide 2.4 mg weekly achieved an average of approximately 15% body weight reduction over 68 weeks. Importantly, among participants who entered the trial with prediabetes, a significant majority had normalized blood sugar levels (returned to the non-diabetic range) by the end of the study. This is an extraordinary metabolic outcome — not just weight loss, but actual reversal of a pre-disease state.
SURMOUNT-1 Trial Evidence (Tirzepatide)
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, showed that tirzepatide (a dual GIP/GLP-1 agonist) produced even greater weight loss — approximately 21% of body weight at the highest dose — in adults with obesity without type 2 diabetes. A significant proportion of participants with baseline prediabetes showed normalization of glycemic markers. At the 5-year follow-up data reported in subsequent analyses, sustained prevention of diabetes progression was maintained in a high percentage of responders.
Glycemic Mechanism
Beyond weight loss, GLP-1 agonists have direct effects on glucose homeostasis that are relevant in prediabetes. They enhance pancreatic insulin secretion in a glucose-dependent manner, suppress postprandial glucagon, and slow gastric emptying — all of which reduce both fasting and post-meal blood sugar spikes. The result is a dual action: weight loss reduces the fat-driven insulin resistance, while the direct pancreatic effects improve beta-cell function before it burns out under the strain of chronic overcompensation.
HbA1c Target Outcomes: What to Expect
At Scale Solutions, we track HbA1c at baseline and at regular intervals during treatment. In patients with prediabetes (A1c 5.7–6.4%) who achieve meaningful weight loss on GLP-1 therapy:
- Many patients see A1c return to the normal range (below 5.7%) within 3–6 months of achieving 10% or greater weight loss
- Even patients who do not fully normalize A1c typically see meaningful reductions — a shift from 6.3% to 5.9%, for example, represents a substantial reduction in long-term diabetes risk
- Improvements in fasting glucose often precede A1c changes, as A1c reflects a 3-month blood sugar average
These are goals — not guarantees. Individual response varies based on duration of prediabetes, degree of existing insulin resistance, age, genetics, and adherence to the full treatment program.
Lifestyle Co-Requirements: Medication Is Not a Replacement
GLP-1 medications are most effective when combined with lifestyle changes. This is not a marketing statement — it is what the clinical trials show. In the STEP-1 trial, all participants received lifestyle counseling alongside semaglutide. The results reflected a combination approach, not the drug alone.
At Scale Solutions, we work with patients on:
- Dietary modification: Reducing refined carbohydrates and processed sugars has the most direct impact on post-meal blood sugar spikes. We do not mandate a single diet approach, but we do provide practical guidance on reducing glycemic load.
- Physical activity: The DPP target of 150 minutes of moderate-intensity exercise per week remains the standard recommendation. We acknowledge that Savannah’s summer heat makes outdoor activity genuinely difficult for 4–5 months per year — indoor activity alternatives, resistance training, and movement throughout the day are equally valid.
- Sleep and stress: Both sleep deprivation and chronic stress worsen insulin resistance. These are not secondary factors — they directly affect blood glucose regulation and deserve attention alongside diet and exercise.
- Regular lab monitoring: We recheck fasting glucose, HbA1c, and insulin levels at regular intervals. Seeing your numbers improve is one of the most powerful motivators for sustained behavior change.
Who Qualifies for GLP-1 Therapy for Prediabetes at Scale Solutions
A typical candidate profile for GLP-1 therapy in the context of prediabetes includes:
- A1c in the prediabetic range (5.7–6.4%) confirmed on labs
- BMI of 27 or higher (the FDA threshold for GLP-1 weight management approval when at least one comorbidity is present — prediabetes qualifies)
- Prior attempt at lifestyle modification with inadequate blood sugar improvement
- No contraindications (personal or family history of medullary thyroid cancer or MEN2, severe GI disease, etc.)
- Motivation for sustained treatment and follow-up
Some patients also qualify under the straight BMI ≥30 threshold regardless of additional comorbidities. Dr. Gates will review your labs, family history, and goals during your initial evaluation.
Why Act on Prediabetes Now?
The window to prevent or reverse prediabetes is real, but it is not unlimited. Over time, persistent elevated glucose causes cumulative damage to the pancreatic beta cells that produce insulin. Once those cells are meaningfully depleted, reversal becomes much harder — and managing type 2 diabetes becomes the new reality. The cost of type 2 diabetes in terms of health, medications, monitoring supplies, and quality of life is substantial.
Acting during the prediabetes stage — when the metabolic machinery is still largely intact — is dramatically more effective than waiting. Our job at Scale Solutions is to help you make the most of that window.
If you have a recent A1c result in the prediabetic range, or if you have not been tested and want to know where you stand, our medical weight loss program starts with exactly this kind of evaluation. Learn more about our locations in Savannah, Pooler, and Hinesville, or call (912) 352-7546.
Frequently Asked Questions: GLP-1 for Prediabetes
Is a GLP-1 medication appropriate if my A1c is only 5.8%?
An A1c of 5.8% is officially in the prediabetic range. Whether GLP-1 therapy is appropriate for you at that level depends on your full clinical picture — your BMI, other metabolic markers, family history, and whether lifestyle changes alone have been tried. This is a physician-judgment call, not an automatic formula.
Can prediabetes be fully reversed?
Yes, for many patients. Return of A1c to below 5.7% is achievable with sufficient weight loss. The STEP-1 trial showed this in a significant proportion of participants. “Remission” of prediabetes is not permanent if weight is regained, but sustained weight loss produces sustained metabolic benefit.
Does insurance cover GLP-1 medications for prediabetes?
Coverage varies widely by insurer. Prediabetes may or may not meet a specific insurance plan’s criteria for GLP-1 coverage — many plans require a type 2 diabetes diagnosis. Self-pay options are available. See our pricing page for details on Scale Solutions’ self-pay program.
This page is for informational purposes only and is not medical advice. Consult Dr. Gates or another qualified clinician before starting any treatment.